{"nct_id":"NCT05840211","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-09","start_date":"2023-05-08","start_date_type":"ACTUAL","primary_completion_date":"2028-04","primary_completion_date_type":"ESTIMATED","completion_date":"2028-04","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["GILD"]}